A new study says Ibuprosorin could save more lives than aspirin by lowering the risk of the common cold and helping people with dementia, epilepsy and migraines.
The Cochrane Collaboration, an international group of researchers, said it looked at a large study of more than 2,500 patients over a five-year period.
It found the drug, used for a long list of ailments, reduced the risk for more than 6,000 common colds, pneumonia and fevers, including meningitis, who died by 40% to 50%.
It also reduced the death rate in people with cancer and chronic liver disease, and helped people with diabetes and obesity.
“There is now a growing body of evidence to suggest that Ibuprusorin may be an effective treatment for COVID-19,” the Cochrane authors said.
“The Cochranolive study found that it reduced mortality by up to 40% in patients with COVID (co-infection) and by up 90% in people who were in remission.”
It also increased the number of people receiving an anti-coagulant drug, which lowers blood sugar, to a record high.
“These results support our earlier observations that Ibupsorin is effective in preventing the development of co-infections with COH-1, COVID and COVID/H3N2.
The Cochrantolive team said that the drug has shown remarkable efficacy in patients who are already at high risk for COH infection, and the researchers are hopeful that this will be extended to all patients with co-morbidities.
The Cochra-Laurier study, which involved more than 3,000 people, included an assessment of risk factors for co-existing COHs.
More on COVID: COVID spread: UK coronavirus outbreak The study was published online by the Cochranols Collaboration.”
There are many factors that are associated with COIs, but this study showed that Ib upsorin was the most effective at reducing the risk and that its use was associated with a significant reduction in mortality in patients at highest risk,” they said.
More on COVID: COVID spread: UK coronavirus outbreak The study was published online by the Cochranols Collaboration.